05.21.24 -- What Time Is Best To Bring My CDMO On Board?

Delve into the intricacies of biopharmaceutical innovation and cutting-edge insights in this e-book as a team of accomplished CDMO experts helps you navigate the complexities of biologics development.

GMP-Source, which is a term we coined, serves the purpose as a highly qualified raw material for a generation of virus, messenger RNA template, and transgenic expression of proteins. 

Learn more about the leading oncolytic viruses, the leading cell lines, and how to strategize your oncolytic virus production plan.

Recent advancements in genetic engineering, analytics, and screening reimagine E. coli as an “optimal” protein factory, not just a common one or an expression system artifact.

Explore the challenges to effective delivery of drugs to the eye, intricacies of ophthalmic drug delivery, and advantages of nanoparticles as an enabling technology for ocular drug-delivery systems.

We discuss the trends in new molecular formats, which are one of the current drivers of renewed interest in fermentation technologies, along with some of their challenges. 

PMs must be technically adept enough to understand a project, but their main role is to ensure it delivers in terms of scope and budget.

To ensure that your adeno-associated virus (AAV) therapy reaches patients as soon as possible, begin your relationship with an experienced AAV manufacturer early in the development journey.

A partnership between Cytiva and Teva Pharmaceuticals showcases tech transfer success through effective communication, diligent project management, and a wide range of expertise.